研究单位：[1]Suzhou Puhe Pharmaceutical Technology Co., LTD[2]Puhe Biopharma[3]Anhui Provincial Hospital,Hefei,Anhui,China,230000[4]The First Affiliated Hospital of Bengbu Medical Colleg,Bengbu,Anhui,China,233000[5]Anhui Provincial Chest Hospital,Hefei,Anhui,China,230000[6]Yijishan Hospital of Wannan Medical College,Wuhu,Anhui,China,241000[7]Beijing Chest Hospital, Capital Medical University,Beijing,Beijing,China,100102[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400000[9]The Second Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400000[10]Fujian Provincial Cancer Hospital,Fuzhou,Fujian,China,350000[11]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361000[12]Gansu Provincial Cancer Hospital,Lanzhou,Gansu,China,730030[13]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510000[14]Cancer Hospital Affiliated to Guangzhou Medical University,Guangzhou,Guangdong,China,510080[15]The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong,China,510080[16]People''s Hospital of Zhongshan City,Zhongshan,Guangdong,China,528400[17]Guizhou Provincial People's Hospital,Guiyang,Guizhou,China,550000[18]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[19]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[20]he First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,471000[21]Henan Cancer Hospital,Zhengzhou,Henan,China,450000[22]The First Affiliated Hospital of Zhengzhou University,Zhenzhou,Henan,China,450000[23]Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[24]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[25]Hunan Cancer Hospital,Changsha,Hunan,China,410000[26]Third Xiangya Hospital, Central South University,Changsha,Hunan,China,410000[27]Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China,010000[28]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210000[29]The Second Affiliated Hospital of Soochow Universit,Suzhou,Jiangsu,China,215000[30]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330000[31]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330000[32]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China,l330000[33]Jilin Provincial Cancer Hospital,Changchun,Jilin,China,130000[34]he First Affiliated Hospital of China Medical University,Shenyang,Liaoning,China,110000[35]Cancer Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,China,250000[36]Qilu Hospital of Shandong University,Jinan,Shandong,China,250000[37]Affiliated Hospital of Jining Medical University,Jining,Shandong,China,272000[38]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266000[39]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200000[40]Shanxi Cancer Hospital,Taiyuan,Shanxi,China,030000[41]the First Affiliated Hospital[42]Medical College of Xi''an Jiaotong University,Xian,Shanxi,China,710000[43]The Second Affiliated Hospital of PLA Air Force Medical University,Xian,Shanxi,China,710000[44]Sichuan Provincial People''s Hospital,Chengdu,Sichuan,China,610000[45]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610000[46]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300000[47]Yunnan Cancer Hospital,Kunming,Yunnan,China,650000[48]Cancer in Zhejiang Province,Hangzhou,Zhejiang,China,310000[49]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310000[50]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310000[51]Taizhou First People''s Hospital,Taizhou,Zhejiang,China,318000[52]Taizhou Hospital of Zhejiang Provinc
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups YK-029A group or Platinum-based chemotherapy group. Participants will receive YK-029A orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
